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M am m alian T arget of R apam ycin Is a C ritical R egulator of 
C ard iac H ypertrophy  in Spontaneously H ypertensive R ats
Will Soesanto, Han-yi Lin, Eric Hu, Shane Lefler, Sheldon E. Litwin, Sandra Sena, E. Dale Abel,
J. David Symons, Thunder Jalili
Abstract— Evidence exists that protein kinase C and the m ammalian target o f rapam ycin are important regulators o f cardiac 
hypertrophy. W e exam ined the contribution o f these signaling kinases to cardiac growth in spontaneously hypertensive 
rats (SHRs). Systolic blood pressure was increased (P < 0 .001 ) at 10 weeks in SHRs versus W istar-K yoto controls 
(162± 3 versus 128±1 mm Hg) and was further elevated (P < 0 .001 ) at 17 weeks in SHRs (1 8 4 ± 7  mm Hg). Heart:body 
weight ratio was not different between groups at 10 weeks but was 22% greater (P < 0 .01 ) in SHRs versus W istar-Kyoto 
controls at 17 weeks. A t 10 weeks, activation o f Akt and S6  ribosomal protein was greater (P < 0 .01 ) in SHRs but 
returned to normal by 17 weeks. In contrast, SHRs had protein kinase C activation only at 17 weeks. To determine 
whether m ammalian target o f rapamycin regulates the initial developm ent o f hypertrophy, rats were treated with 
rapam ycin (2 mg/kg per day IP) or saline vehicle from 13 to 16 weeks o f age. Rapam ycin inhibited cardiac mammalian 
target o f rapam ycin in SHRs, as evidenced by reductions (P < 0 .001 ) in phosphorylation o f S6  ribosomal protein and 
eukaryotic translation initiation factor-4E binding protein 1. Rapam ycin treatm ent also reduced (P < 0 .001 ) heart weight 
and hypertrophy by 47%  and 53% , respectively, in SHRs in spite o f increased (P < 0 .001 ) systolic b lood pressure versus 
untreated SHRs (21 3 ± 8  versus 18 9 ± 6  mm Hg). Atrial natriuretic peptide, brain natriuretic peptide, and cardiac function 
were unchanged between SHRs treated with rapam ycin or vehicle. These data show that m ammalian target o f rapamycin 
is required for the developm ent o f cardiac hypertrophy evoked by rising blood pressure in SHRs. (H ypertension. 2009; 
54:1321-1327.)
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/^ V  vcr the last dccadc. much research has focused on 
V ^ /  identifying the signaling pathways that regulate cardiac 
hypertrophy. Among these pathways, protein kinase C (PKC) 
and the mammalian target of rapamycin (mTOR) have emerged 
as potentially important regulators of cardiac hypertrophy.1
PKC is a family of scrinc-threonine kinases consisting of 
11 isoforms in the heart.’ Studies using transgenic mice with 
cardiac specific overexpression of PKC /3II or e. and mice 
with overexpression of peptide activators o f PKC ft and e. 
have reported that these isoforms regulate pathological (PKC 
/3II) and/or physiological cardiac hypertrophy (PKC ft and e ).3~6 
Similarly, humans with hypertrophy and heart failure exhibit 
activation of PKC-a and ~/3U.7
Signaling through components of the mTOR pathway is an 
important regulator of normal cardiac growth and patholog­
ical hypertrophy. For example, overexpression of phospho- 
inositide 3-kinase in mice results in Akt activation and 
increased heart size, whereas overexpression of dominant- 
negative phosphoinositide 3-kinase leads to decreased Akt 
activation and rcduccd heart size.8 Other studies using 
cardiac-specific overexpression of Akt report that develop­
ment of both physiological and pathological hypertrophy is
correlated with the degree of Akt activation .9-10 Human 
studies examining components of mTOR signaling during 
hypertrophy or heart failure arc scarce, and what data exists is 
conflicting. For example, it has been reported that implanta­
tion of a left ventricular assist device in patients with heart 
failure resulted in cardiac improvements (rcduccd left ven­
tricular end-diastolic dimensions and apoptosis). associated 
with a reduction in phosphorylatcd (p)-Akt.11 In contrast, a 
more recent study stated that hypertensive patients without 
heart failure had higher p-Akt than patients with heart 
failure.1’ Therefore, the role of the mTOR signaling pathway 
during human hypertrophy and heart failure remains unclear.
In the present study, we tested the hypothesis that PKC and 
mTOR contribute to cardiac hypertrophy that develops in 
spontaneously hypertensive rats (SHRs). We chose the SHR 
because these animals model human hypertension and cardiac 
growth. In this regard, these rats arc normotensive at 6  weeks 
of age but develop hypertension and cardiac hypertrophy at 
«“ 12 weeks of age and heart failure by ^ 2 4  months.13-14 Data 
provided herein show that signaling via mTOR. but not PKC. 
is increased in SHRs during the development of cardiac 
hypertrophy (ic. at 10 weeks). Furthermore, when mTOR was
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inhibited using rapamycin. cardiac hypertrophy was attenu­
ated independent of changes in blood pressure. These data 
show clearly that mTOR is required for the initiation and full 
development of cardiac hypertrophy evoked by rising blood 
pressure in SHRs.
M ethods
Please see the online Data Supplement at http://hyper.ahajoumals.org 
fo r a detailed description o f the methods and experimental groups.
Animals
A l l  o f  the protocols were approved b y  the U n ive rs ity  o f  Utah 
Ins titu tiona l A n im a l Care and Use C om m ittee. S ix-w eek--o ld  male 
SHRs (n = 4 2 ) and W is ta r K yo to  rats (W K Y s ; n = 2 4 ) were purchased 
from  Harlan (Indianapolis. IN ) and housed in the U n ive rs ity  o f  U tah 
Com parative M ed ic ine  Center under standard conditions (12112- 
hour ligh trda rk  cycle) and were a llow ed free access to food and 
water. Rapam ycin was purchased from  L C  Laboratories.
Blood Pressure
B lood  pressure was measured using a f lu id - f i l le d  catheter placed into 
the caudal artery o f  rats anesthetized w ith  2%  to 5% iso tlu rane .I5' 16 
A fte r  rats regained consciousness, b lood  pressure was measured over 
20 cardiac cycles.
RNA Extraction and Quantitative RT-PCR
Tota l R N A  was extracted from  the le ft ven tric le (L V )  using T R lzo l 
reagent (Inv itrogen) and p u rif ie d  using the R N easy to ta l R N A  
iso la tio n  k i t  (Q iagen). R T -P C R  was done as de ta iled  b y  B oud in a  
et a l .17
Tissue Homogenization and Western Blotting
H om ogenization o f the L V . electrophoresis, and transfer o f  proteins 
to po lyv in y lid cne  d ifluo ride  membranes were done as we have 
described p re v ious ly .1819 W estern b lo ts were ve rifie d  in  duplicate i f  
no s ign ifican t differences were observed o r trip lica te  i f  s ign ifican t 
differences were present.
Myocardial Function
Cardiac function was determ ined in a subset o f  SHRs a fte r 3 weeks 
o f  rapamycin (2 m g /kg  IP ; n = 5 )  or vehicle (saline; n = 5 )  treatment 
using echocard iography.15
Statistical Analysis
A n  A N O V A  was used to detect d ifferences among groups using 
SPSS version 11 fo r M acin tosh (SPSS Inc). When a s ign ifican t P  
value was obtained ( /J< 0 .0 5 ). post hoc procedures were perform ed 
using the least s ign ifican t d ifference analysis to id e n tify  ind iv id ua l 
group differences. Results are presented as m ean±S E .
R esu lts
PKC, mTOR, Cardiac Mass, and Blood Pressure 
in 10-Week- and 17-Week-Old SHRs
At 10 weeks of age. hcart:body weight ratio was similar in 
WKYs versus SHRs (Table 1). In contrast, cardiac hypertro­
phy was present in 17-wcck-old SHRs. as evidenced by 
increased hcart:body weight ratio versus WKYs (Table 1). 
Systolic blood pressure was 26% higher in 10-wcck-old 
SHRs compared with WKYs and 33% greater in 17-wcck- 
old SHRs versus WKYs (Table 1).
There were no differences detected in total protein expres­
sion of PKC-a. PKC-/3IL. PKC-fi. or PKC-s in SHRs versus 
WKYs at either age (Figure 1A; data not shown for PKCfi). 
Levels of p-PKC-e were also similar at both ages of SHRs
Table 1. Characteristics of WKYs and SHRs
Group 10-wk WKY 10-wk SHR 17-wk WKY 17-wk SHR
No. 6 6 6 6
Heart weight, mg 1015±54 1183 ± 29* 1048 ±35 1297±43f
Body weight, g 245 ±5 297±5* 319± 10 325 ±1 Of
Heartbody weight, 3.95±0.11 3.99±0.09 3.32±0.14 3.99±0.10t
mg:g
Heart rate 398±10 410±8 422± 14 480±18f
Caudal blood
pressure, mm Hg
Systolic 128±1 162±3* 138±2 184±7f
Diastolic 109±2 148 ± 2* 114±3 159±5f
Mean arterial 116±1 152±2* 122± 2 167 ± 4f
pressure
Data are mean±SE. WKY indicates normotensive control rats. 
*P<0.05 vs 10-week-old WKYs. 
tP<0.05 vs 17-week-old WKYs.
and WKYs (Figure 1A). p-PKC-fi was not detected in the 
myocardium of SHRs or WKYs. This might be because of a 
lack of specificity of the primary antibody against rat heart 
p-PKC-fi rather than an absence of p-PKC-fi. There was no 
change in p-PKC-a//3II in 10-wcck-old SHRs compared with 
their age-matched controls. However. 17-wcck-old SHRs 
had an ^ 8 0 %  increase in p-PKC-a//3II versus WKYs (Figure 
1A). To control for any possible protein loading differ­
ences. the p-PKC-a//3II:total PKC-/3II ratio was deter­
mined and found to be significantly greater in 17-wcck- 
old SHRs versus WKYs (Figure 1A). Similar results were 
obtained with the p-PKC-a//3II:total P K C a ratio (data not 
shown). After these initial experiments, we also examined 
PKC status at 14.5 weeks in a subset o f SHRs and WKYs 
but found no change in p-PKC-a//3II at this age (data not 
shown). p-AktScr473 and the ratio o f p-AktScr473: total Akt 
were «=70% greater in 10-w cck-old SHRs but unchanged 
in 17-w cck-old SHRs compared with age-matched WKYs 
(Figure IB). GAPDH protein expression, used as a loading 
control, was sim ilar among all of the groups (Figure IB).
mTOR Signaling and Cardiovascular Variables in 
Rats Treated With Rapamycin
We reasoned that mTOR signaling might regulate the devel­
opment o f hypertrophy, because both Akt and S6 phosphor­
ylation were greater at 10 but not 17 weeks in SHRs versus 
WKYs. To address this. 13-wcck-old SHRs were treated 
with rapamycin or vehicle for 3 weeks, a duration similar to 
those used in prcssurc-ovcrload experiments.20 In this exper­
iment we did not use a rapamycin-trcatcd WKY group 
because cardiac mass has been reported to be unaffected by 
this drug in control animals.20-21 Thirtccn-wcck-old SHRs 
were chosen because our preliminary studies indicated that 
cardiac hypertrophy is minimal at this time, and p-AKT is 
still elevated, whereas p-PKCa//3II is normal in 14.5-wcck- 
old SHRs. Inhibition of mTOR signaling by our rapamycin 
treatment regimen (Rap) was confirmed by ^4-fo ld  reduction 
in levels o f V s 6 Scr235/236 and p-4E-BPlThr37/46 in SHR-Rap 
versus SHR-Vch and WKY-Vch (vehicle; Figure 2). 
p-AktScr473 was reduced ^80%  in SHR-Rap (Figure 2).
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Figure 1. A, W estern b lo t ana lysis o f P KC -n, -0 II, and -« in hearts  o f 1 0 -w e e k -o ld  SHRs du ring  the  deve lopm ent phase o f ca rd iac  hy­
p e rtro p h y  and 1 7 -w e e k -o ld  SH Rs w ith  estab lished ca rd iac  hypertrophy. B ar graphs represent fo ld  change  o f p -P K C -« /0 ll:to ta l P KC -0II 
in SHRs vs W KYs. B, W estern b lo ts  o f A k t and  S6 in hearts  o f 10 w e e k -o ld  SHRs du ring  the  deve lopm ent phase o f ca rd iac  hyp e rtro ­
ph y  and 17 -w eeks-o ld  SH Rs w ith  es tab lished ca rd iac  hypertrophy. B ar g raphs represent fo ld  changes in p -A k tSer473:to ta l A k t and 
p -S 6 :to ta l S6 in S H Rs vs ag e -m a tched  W KYs. For all o f the  experim ents, G APDH w as used as a load ing  con tro l. For all o f the  ba r 
graphs, da ta  are presented  as m e an±S E ; n = 6  in all o f the  groups. 'S ig n ific a n t d iffe rence a t P < 0 .0 5 .
Taken together, signaling through mTOR in the heart was 
markedly reduced in rapamycin-trcatcd SHRs.
Heart weights were lower in SHR-Rap rats than SHR-Vch 
rats but still greater than WKY-Vch rats (Table 2). As 
expected, blood pressure was greater in SHRs versus WKYs, 
but surprisingly it was even higher in SHR-Rap rats versus 
SHR-Vch rats (Table 2). Rapamycin-trcatcd SHRs had lower 
body weight than WKY-Vch or SHR-Vch rats (Tabic 2). 
Heart mass was, therefore, normalized to tibia length for the 
rapamycin studies. In spite of increased blood pressure in the 
SHR-Rap rats, cardiac hypertrophy was attenuated (heart: 
tibia length) versus SHR-Vch rats but was still greater than 
WKY-Vch rats (Figure 3A and 3B). Expression of atrial 
natriuretic peptide (ANP) and brain natriuretic peptide 
(BNP), markers of pathological cardiac hypertrophy and 
increased wall stress, was elevated in SHR-Vch versus 
WKY-Vch rats. Although hypertrophy was attenuated in 
SHR-Rap rats, the expression of ANP and BNP remained 
similar to SHR-Vch rats (Figure 3C).
It is possible that the combination of exaggerated hyper­
tension and attenuated hypertrophy in SHR-Rap versus SHR- 
Vch rats might lead to increased wall stress and cardiac
dysfunction. However, there was no echocardiographic evi­
dence for LV dysfunction, bccausc both ejection fraction and 
fractional shortening were similar in SHR-Vch and SHR-Rap 
rats (Figure 3D). Interventricular septal dimension, left ven­
tricular diastolic dimension, and left ventricular posterior wall 
dimension were also similar in SHR-Rap versus SHR-Vch 
rats (data not shown).
D iscussion
The contribution of mTOR signaling to cardiac hypertrophy 
that develops in response to a gradual increase in aftcrload, as 
occurs in the SHR, is unknown. In the present study, we 
observed activation of mTOR signaling in hearts of young 
SHRs during the developmental stage of cardiac hypertrophy. 
Pharmacologically inhibiting this pathway attenuated the 
extent of cardiac hypertrophy that ultimately occurs in this 
model. These arc the first data indicating that mTOR signal­
ing contributes importantly to cardiac hypertrophy in a 
clinically relevant model of hypertension.
Studies using pressure-overloaded mice and guinea pigs 
reported that P70 S6 ribosomal kinase phosphorylation is 
clearly correlated with cardiac hypertrophy’1’’ and that
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Figure 2. Im p ac t o f rapam ycin  tre a tm e n t on 
m T O R -regu la ted  s igna ling  k inases. Bar g raphs 
represent fo ld  changes in p -A k tSer473:to ta l A k t and 
p -S 6 :to ta l S6. Bar g raphs fo r 4E-BP1 represent 
fo ld  change in p-4E-BP1 and to ta l 4E-BP1 in 
SH Rs vs age -m a tched  W KYs. The ra tio  o f p -4E - 
BP1 :to ta l 4E-BP1 is no t show n because it do es  
no t con vey  the  severe reduc tion  in b o th  4E-BP1 
p h ospho ry la tio n  and to ta l 4E-BP1 p ro te in  th a t is 
ev iden t fro m  the  b lo ts  them se lves. For all o f the  
experim ents , GAPDH w as used as a load ing  c o n ­
tro l. W K Y  ind ica tes  W KY s tre a ted  w ith  sa line veh i­
cle; SHR, S H Rs tre a ted  w ith  sa line veh ic le ; S H R- 
Rap, spon tan eou s ly  hypertens ive  ra ts  tre a ted  w ith  
rapam ycin . n = 7  W KY; n = 6  SHR; n = 9  S H R -R ap. 
*P < 0 ,0 5  vs W KY s and SHRs.
□  p-4E-BP1 Thr37 /46 □  4E-BP1
cardiac-spccific Akt overexpression increases activation of 
mTOR and results in cardiac hypertrophy.91023 The in vivo 
importance of mTOR has also been demonstrated in pressure- 
overloaded rodents where rapamycin treatment results in 
inhibition of mTOR. as determined by downstream cffcctors. 
such as P70 S6 ribosomal kinase, and attenuates cardiac
Table 2. Characteristics of WKYs and SHRs Treated With 
Vehicle or 2 mg/kg of Rapamycin
Variable WKY-Veh SHR-Veh SHR-Rap
Age, wk 16 16 16
No. 7 11 14
Heart weight, mg 827 ±26 1244±21* 1080 ±18*t
Body weight, g 252 ±4 322±3* 269±3*t
Tibia length, mm 36.1 ±0.2 38.3±0.2* 38.0±0.2*
No. 7 6 9
Heart rate, bpm 376±11 O+i005CO 405 ±13
Caudal blood pressure, mm Hg
Systolic 139±6 189 ± 7* 213±6*t
Diastolic 118±6 156±7* 171 ±6*
Mean arterial pressure 125±6 167 ±7* 184±5*t
Data are mean±SE. WKY indicates normotensive control rats treated with
saline vehicle (Veh IP from 13 to 16 weeks of age). SHR-Rap rats were treated 
with 2 mg/kg of rapamycin from 13 to 16 weeks of age.
*P<0.05 vs WKYs. 
tP<0.05 vs SHRs.
hypertrophy evoked by aortic constriction.21- 4- 5 The studies 
using pressure-overloaded models arc important; however, it 
should be noted that aortic constriction crcatcs local hyper­
tension and docs so in an abrupt manner. This proccss differs 
from the SHR that has gradually increasing systcmic hyper­
tension that eventually results in cardiac hypertrophy. The 
SHR may be considered to be more clinically relevant to the 
human cxpcricncc. where uncontrolled hypertension leads to 
cardiac hypertrophy. In the present study, rapamycin-trcatcd 
SHRs demonstrated a d ea r and robust reduction in the 
phosphorylation of S6 and 4E-BP1. both downstream targets 
of mTOR. and. thus, provided mechanistic cvidcncc of the 
role of mTOR in the development of cardiac hypertrophy.
PKC isoforms have been reported to be mediators of 
cardiac function and hypertrophy. Overexpression or activa­
tion o fP K C -p i. -e. and -ft has been found to result in cardiac 
hypertrophy in micc.26 Interestingly, micc with deletion of 
PKC-/3 still develop cardiac hypertrophy in response to 
pressure overload or phenylephrine.27 and overexpression of 
PKC-a docs not causc cardiac hypertrophy but results in 
diminished ventricular function .28 Similarly, inhibition of 
conventional PKC isoforms (a. f3. and 7 ) increases cardiac 
function in micc.29 whereas adenoviral transfcction of PKC-a 
rcduccs cardiac contractility in the normally hypcrcontractilc 
PKC-a knockout mouse.30 In contrast to our original hypoth­
esis. wc did not find activation of any PKC isoform in 
10-wcck-old SHRs during the developmental phase of car-
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F ig u re  3. A , Index o f ca rd iac  h yp e rtrophy  
exp ressed as heart w e ig h tt ib ia  leng th  in 
ra ts trea ted  w ith  rapam ycin  a t 2 m g /kg  
(Rap) o r veh ic le  (saline) fro m  13 to  16 
w eeks o f age ( n - 7  W KY; n = 7  SHR; n = 9  
S HR-Rap). H e a r tb o d y  w e igh t w as not 
used because  o f w e igh t loss  tha t 
occu rred  in S H R s a fte r rapam ycin  tre a t­
m ent. B, H e a r tt ib ia  leng th  p lo tted  aga ins t 
m ean arteria l b loo d  pressure  (MAP) illus ­
tra tes  a ttenua tion  o f card iac  hype rtrophy  
in S H R -R ap ra ts  in sp ite  o f s ign ifica n tly  
increased b loo d  pressure  com pared  w ith  
SH R-Veh ra ts  ( n - 7  W KY; n = 7  SHR; n = 9  
S HR-Rap). C, m R N A exp ress ion  o f ANP 
and BNP ( n - 7  W KY-Veh; n = 7  SHR-Veh; 
n = 9  SHR-Rap). D, In v ivo  assessm ent o f 
card iac  fu n c tio n  us ing pa ram eters o f pe r­
cen tage o f frac tiona l sho rten ing  (FS) and 
e jec tion  fra c tion  (EF; n = 5  SHR; n = 5  S H R - 
Rap). W K Y  ind ica tes  W KY s trea ted  w ith  
sa line veh ic le ; SHR, SH Rs trea ted  w ith  
sa line veh ic le ; S H R-R ap, S H R s trea ted  
w ith  rapam ycin . * P < 0.05 vs W KYs. 
fP < 0 .0 5  vs S H R-Veh rats.
diac hypertrophy. However. 17-week-old SHRs had an 
increase in p-PKC-a//3II. Although no other studies have 
examined PKC during the developmental phase of hypertro­
phy in the SHR. others have found PKC-a. -S. and -e 
activation in 6 -m onth-old spontaneously hypertensive heart 
failure rats31 and PKC-/3 activation in 16-week-old Dahl 
salt-sensitive rats.32 Given the lack of PKC activation in 
hypertensive 10-week-old SHRs without hypertrophy, one 
may speculate that the PKC alterations in spontaneously 
hypertensive heart failure rats and Dahl salt-sensitive rats 
with established hypertrophy may be related to the regulation 
of cardiac function rather than growth.
In the present study, we found that treating SHRs with 
rapamycin for 3 weeks resulted in even greater blood pressure 
compared with vehicle-treated SHRs. This is consistent with 
previous studies reporting detrimental changes in kidney 
function, along with tubular atrophy and vascular pathology, 
after treating with 0.8  mg/g of rapamycin for 2 weeks.33-34 
Although hypertension has not been a reported adverse effect 
in human clinical trials using long-term rapamycin treatment 
for immunosuppression.35 it should be noted that clinical use 
uses a lower dose of rapamycin compared with animal 
studies, such as the present one. Another observed adverse 
effect of rapamycin treatment was the weight loss that 
occurred in the SHR-Rap group. Although no other studies 
have used rapamycin to attenuate hypertrophy in genetically 
hypertensive models, several studies have used similar dos­
ages of rapamycin in pressure-overloaded mice and rats. 
Studies using mice have not observed changes in body weight 
after either I21-25 or 4 weeks20 of treatment with rapamycin. 
whereas pressure-overloaded rats show significant weight
loss even after just 3 days of rapamycin.24 To our knowledge, 
the present study is the first to treat SHRs with rapamycin.
It is seemingly contradictory that rapamycin treatment 
attenuated cardiac hypertrophy in SHRs in spite of greater 
blood pressure; however, this underscores the importance of 
mTOR signaling in stimulating cardiac growth during the 
developmental phase of hypertrophy. Given the persistence of 
this pathological stimulus (hypertension) in SHR-Rap rats, it 
is also not surprising that expression of ANP and BNP. both 
markers of pathological cardiac hypertrophy or increased 
wall stress, remained increased. Therefore, it appears that the 
reduction in hypertrophy after rapamycin treatment is attrib­
utable solely to the inhibition of mTOR. without fundamen­
tally altering the pathological nature of the residual hypertro­
phy that develops in SHR-Rap rats or the increase in wall 
stress. Given the disproportional degree of hypertrophy ver­
sus hypertension in rapamycin-trcatcd SHRs. wc used echo­
cardiography to evaluate ejection fraction and fractional 
shortening as measures of cardiac function. Wc have reported 
previously that 16-wcck-old SHRs with cardiac hypertrophy 
have normal cardiac function compared with agc-matchcd 
W KYs.36 In the present study, our data indicated that both 
ejection fraction and fractional shortening were also similar 
in vchiclc and rapamycin-trcatcd SHRs. Wc concludc that 
short-term rapamycin treatment docs not adversely affect 
cardiac function; however, the cffcct of an extended (> 3  
weeks) period of rapamycin treatment on cardiac function 
remains unknown. A limitation, however, of the present study 
is the lack of histological analysis of hearts from rapamycin- 
trcatcd and untreated SHRs. Histological analyses from 
previous studies indicate that myocyte size is increased in
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14-wcck-old SHRs,37 whereas cardiac fibrosis develops be­
tween 12 and 20 months of age.38 However, in the present 
study, it is unknown to what degree rapamycin treatment may 
have altered cardiac structure with regard to myocyte size in
16-wcck-old SHRs.
Perspectives
Recent studies have reported that sirolimus (rapamycin) 
treatment can reduce LV hypertrophy in humans that is an 
adverse effect of kidney transplant39 and heart transplant.40'41 
Not surprisingly, these reports have led to suggestions that 
rapamycin may have therapeutic potential for treating LV 
hypertrophy in cardiac transplant patients, as well as those 
with other etiologies, such as hypertension and myocardial 
infarction. However, our data indicate several factors that 
should be seriously considered in this regard. For example, 
transplant patients examined in previous studies did not have 
hypertension40'41 or were under pharmacological blood pres­
sure control,39 whereas SHRs used in our study were severely 
hypertensive. This point is noteworthy, because our data 
indicate that rapamycin in the face of untreated hypertension 
may worsen the condition. Second, although we achieved 
more substantial reductions in cardiac hypertrophy in our 
study (=“50% reduction in developed hypertrophy) compared 
with those reported in the kidney or heart transplant patients 
(10% and «*5% reduction in LV mass index, respectively), 
our rapamycin doses were much higher in SHRs versus 
patients (2 mg/kg IP per day in SHRs versus human total dose 
of 1 mg PO per day). Although our data suggest that a larger 
reduction of hypertrophy may be possible in clinical situa­
tions, safety and efficacy studies would be required to 
determine a dose of rapamycin that would strike a balance 
between optimal reductions in hypertrophy and reduced 
mortality without severe adverse effects. Finally, we have 
demonstrated in the SHR model that rapamycin markedly 
inhibits S6  and 4E-BP1; however, it is unclear whether this 
near total inhibition is actually required to attenuate cardiac 
hypertrophy. As such, the possibility exists that lower doses 
of rapamycin might be similarly efficacious in this regard. In 
light of this, we believe that further research is warranted to 
elucidate the degree of mTOR inhibition that is associated 
with LVH regression before any assumptions can be made as 
to the potential therapeutic use of rapamycin in patients with 
hypertrophy because of other causes, such as hypertension 
myocardial infarction.
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METHODS
Animals
In the first series of experiments SHR were evaluated at time points when 
hypertension and cardiac growth were developing (10 weeks old, n=6) or 
established (17 weeks old, n=6), and results were compared to an identical 
number of age-matched WKY rats. Because we observed that mTOR signaling 
was increased in 10-week old rats, a second series of experiments was 
performed to test the hypothesis that mTOR is required for development of 
cardiac hypertrophy in these hypertensive animals. In this experiment thirteen- 
week old SHR were treated daily with rapamycin, an inhibitor or mTOR, (2 mg/kg
i.p.; SHR-Rap, n=14) or saline (SHR-Veh, n=11) for 3 weeks, while age-matched 
WKY rats treated with saline served as controls (WKY-Veh, n=7). In these 
experiments we did not use a WKY rapamycin treated group because previous 
studies have shown that rapamycin does not affect cardiac mass in rodents that 
do not have pressure overload1, 2. To determine whether rapamycin 
compromised cardiac function in treated SHR cardiac function was evaluated in a 
subset of 16-week old SHR-Rap and SHR-Veh rats (n=5 per group).
Blood pressure and heart rate
Rats regained consciousness and were allowed to recover for 60-min. 
Arterial blood pressure and heart rate were measured over ~20 cardiac cycles 
(Biopac Systems Inc., Santa Barbara, CA). Next, rats were anesthetized again 
(5%  isoflurane), the heart excised and placed immediately in iced physiological 
saline solution and trimmed of adherent tissue. After hearts were weighed, they 
were snap frozen in liquid nitrogen, and stored at -80oC. The left ventricle (LV) 
was used in subsequent experiments to examine signal transduction pathways.
RNA extraction and quantitative RT-PCR
After atrial natiuretic peptide (ANP) and brain natiuretic peptide (BNP) 
were expressed relative to cyclophilin (CPHN), values were normalized to the 
mean WKY value. Rat primer sequences were: CPHN-for 5 ’- 
AGCACTGGGGAGAAAGGATTTGG-3’, CPHN-rev 5 ’- 
TCTTCTTGCTGGTCTTGCCATT-3’, ANP-for 5 ’-
GGGGGTAGGATTGACAGGAT-3’, ANP-rev 5 ’-CTCCAGGAGGGTATTCACCA- 
3 ’, BNP-for 5 ’-GACGGGCTGAGGTTGTTTTA-3’, BNP-rev 5 ’- 
ACTGTGGCAAGTTTGTGCTG-3’.
Tissue homogenization and Western blotting
All homogenization procedures were performed at 4°C. The LV was 
homogenized with a tissuemizer in 1 ml of ice-cold RIPA buffer [50 mM Tris-HCl 
(pH 7.4), 150  mM NaCl, 1%  Nonidet P-40, 0 .2 5 %  sodium deoxycholate, 1mM 
sodium orthovanadate, 1mM NaF, and 10 (il/mL Sigma protease inhibitor cocktail 
(Sigma, St. Louis, MO, cat. #P-8340)]. After homogenization, samples were 
sonicated on ice and centrifuged at 1 1 ,0 0 0  x g for 10 min at 4°C. Protein 
concentration was determined using a BioRad Protein assay (BioRad, Hercules,
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CA) with bovine serum albumin (BSA) as a standard. Cardiac homogenates were 
stored at - 8 0 oC for subsequent Western blotting.
Antibodies directed against PKCa, pi I, e, 5, and p-PKCsSer729 and GAPDH 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies 
directed against p-AktThr308, p-AktSer473, total Akt, p-PKCa/pilThr638/641 and p- 
PKC8Thr505, S6 ribosomal protein (S6), p_S6ser235/236, eukaryotic translation 
initiation factor-4E binding protein-1 (4E-BP1), p-4E-BP1Thr37/46 were purchased 
from Cell Signal Technology (Beverly, MA). All primary antibodies were 
incubated overnight at 4°C in a 1 :1000 dilution in 5 %  BSA in Tris buffer with
0 . 0 5 .  Tween-20 (phospho specific antibodies) or 5 %  nonfat milk (non-phospho 
specific antibodies). Secondary antibody conjugated to horseradish peroxidase 
(goat anti-rabbit, Cell Signal Technology, Beverly, MA) was incubated for 1 h at 
1:10 ,000  dilution. Signals were visualized by enhanced chemiluminescence (Cell 
Signal Technology, Beverly, MA). After exposure, membranes were stripped and 
probed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading 
control (Chemicon, Temecula, CA). Relative band densities of immunoblots were 
measured using a Kodak GL1500 gel imaging system.
Myocardial Function
Rats were anesthetized with 2 -5%  isoflurane and two dimensional-guided 
M-mode images of the left ventricle were obtained using a General Electric Vivid 
5 echocardiographic machine equipped with a 10-MHz transducer. Digital images 
were analyzed offline by a blinded observer.
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